Abstract: The present invention relates to high-purity titanium monoxide powder (TiO) produced by a process of combining a mixture of titanium suboxides and titanium metal powder or granules; heating and reacting the compacted mixture under controlled atmosphere to achieve temperatures greater than about 1885° C., at which temperature the TiO is liquid; solidifying the liquid TiO to form a body of material; and fragmenting the body to form TiO particles suitable for application as e.g., capacitors. The TiO product is unusually pure in composition and crystallography, highly dense, and can be used for capacitors and for other electronic applications. The method of production of the TiO is robust, does not require high-purity feedstock, and can reclaim value from waste streams associated with the processing of TiO electronic components.

Abstract: Titanium dioxide having a ratio Dtop/D50 of 1 to 3, between the maximum particle diameter Dtop and the average particle diameter D50, as determined based on observing the primary particles by a field emission-type scanning electron microscope. A production process of the titanium dioxide comprises performing a vapor phase process of reacting a titanium tetrachloride-containing gas with an oxidative gas to produce titanium dioxide, wherein when the titanium tetrachloride-containing gas and the oxidative gas are reacted by introducing each gas into a reaction tube, the temperature in the reaction tube is from 1,050 to less than 1,300° C.

Abstract: A system for hydrogen loading is provided. The system includes a substrate, such as that made from palladium, a matrix of nanotubes, for example, SWCNT, disposed on the substrate, and a coating, capable of dissociating hydrogen into its atomic form, covering the matrix of nanotubes. The presence of such a coating on the matrix of SWCNT can lead to a flux of hydrogen across the coating and facilitate loading of hydrogen into the nanotubes, when exposed to hydrogen at an appropriate effective pressure. The system may be also used to generate a thermal response.

Abstract: A method for steam reforming carbonaceous material into a synthesis gas by using a single stage process of heating the carbonaceous material in a rotary kiln at an elevated reforming temperature so that the carbonaceous material undergoes substantially complete conversion to synthesis gas or by using a dual stream, multiple-stage process of heating carbonaceous material to a reforming temperature, below that at which metallic materials will typically vaporize, to form gaseous and solid materials; further reforming the gaseous materials in a second stage reforming kiln at an elevated reforming temperature to form synthesis gas; and separating carbon char from the solid material for further processing.

Abstract: The invention relates to materials for storing and releasing bulk quantities of hydrogen and methods for preparing and using same. The materials exhibit fast release rates at low release temperatures are suitable as hydrogen sources for a variety of applications and devices.

Abstract: The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.

Abstract: Embodiments of the present invention are directed to acoustic data transmission using a spreading code. A system for acoustic data transmission includes an ingestible capsule and an acoustic receiver. The ingestible capsule includes a modulator, a spreader, and an acoustic transmitter. The modulator modulates data according to a modulation scheme. The spreader spreads the modulated data according to a spreading code. The acoustic transmitter acoustically transmits the modulated and spread data through a body of an animal. The acoustic receiver includes an acoustic transducer a de-spreader and a demodulator. The acoustic transducer receives the acoustically transmitted signal and forms an electrical signal therefrom. The de-spreader de-spreads the received signal in accordance with the spreading code.

Abstract: Compositions containing polymeric micro- and nanoparticles with non-spherical shapes and methods for making and using such particles are described herein. The particles have a size range from an average diameter of about Compositions containing polymeric micro- and nanoparticles with non-spherical shapes and methods for making and using such particles are described herein. The particles have one or more dimensions ranging from about 5 nm to about 100 ?m, preferably about 100 nm to 10 ?m. The particles can have any of a wide variety of non-spherical shapes. The particles are generally formed by manipulation of spherical particles embedded in a polymeric film. A wide variety of resulting shapes can be made. The resulting shape is a function of whether the films are manipulated in a first and/or second dimension, and the processes used to liquefy the microparticles. Variations of the method of manufacture may be used to generate particles having the desired shapes in large, reproducible quantities.

Abstract: The present invention provides methods of identifying candidate therapeutic agents for use in the treatment of acute pancreatitis.

Abstract: The present invention provides method for quickly and conveniently determining if a given treatment regimen of IGF1R inhibitor is sufficient, e.g., to saturate IGF1R receptors in the body of a subject. Several clinically relevant determinations may be made based on this point, including, for example, whether the dosage of the regimen is sufficient or should be increased.

Abstract: Described herein are methods for treating a subject suffering from a T-cell lymphoma by administering to the subject a pharmaceutical composition containing a therapeutically effective amount of a selective inhibitor of histone deacetylase 8. Also described herein are methods for treating a subject suffering from a T-cell lymphoma by administering to the subject a population of autologous T-cells that have been exposed to a selective HDAC8 inhibitor composition ex vivo.

Abstract: Isolated mixed populations of fetal pulmonary cells, engineered three-dimensional tissue constructs of these cells, and uses thereof in identifying therapeutic agents which augment, repair, and/or replace dysfunctional native lung and to perform in vitro studies such as pharmaceutical screening, models for lung development and disease and characterization of chemical or mechanical injury are provided.

Abstract: An encapsulated chelate dendritic polymer and an encapsulated ligand dendritic polymer are disclosed which have unique properties. These encapsulated chelate dendritic polymers may have associated with its dendritic polymer surface target directors, proteins, DNA, RNA (including single strands) or any other moieties that will assist in diagnosis, therapy or delivery of this encapsulated chelate dendritic polymer. These encapsulated dendritic polymers are suitable as contrast agents for use in imaging in an animal, for other imaging techniques, for EPR, and as scavenger agents for chelant therapy. Formulations for these uses are also included within the scope of this invention.

Abstract: The subject invention provides an X-ray visible drug delivery device for subdermal administration of a contraceptive or hormone replacement therapy.

Abstract: A solution including a solute of ?-aminobutyric acid dissolved in a solvent is sprayed in a space.

Abstract: Stability of biocompatible polymers of the formula: wherein Z is —C(O)R1; each R1 is independently selected from a linear, branched, or cyclic alkyl, alkoxy, or aryl with 1 to 18 carbon atoms optionally substituted by carbonyl, oxy, thio, and/or nitrogen; each R2 is independently selected from hydrogen or a linear or branched hydrocarbon with 1 to 4 carbon atoms; X is selected from the group consisting of —OR1, —SR1, —N(R1)2 and divalent or trivalent headgroups terminated in oxygen, nitrogen, or sulfur; y is greater than or equal to 1 and less than or equal to 3; is enhanced by providing compositions where there is a low level of —OH end group impurity, i.e., where Z is —H instead of —C(O)R1 and/or X is —OH instead of —OR1, —SR1, —N(R1)2 or divalent or trivalent headgroups terminated in —O—, —N—, or —S—, such that there are no more than 10 of these —OH end groups for every 100 intended biocompatible polymer molecules.

Abstract: A room temperature stable aqueous cannabinoid formulation is disclosed. In preferred embodiments, the cannabinoid formulation comprises dronabinol in a mixture of buffer solution, and organic cosolvents such as ethanol, propylene glycol and polyethylene glycol.

Abstract: Microparticles that are obtainable by spray-freeze-drying a solution comprising a water-soluble, matrix-forming polymer and a therapeutic agent may be useful for pulmonary delivery of the therapeutic agent.

Abstract: A product release system for atomizing cosmetic hair or skin compositions is described, which has (a) pressure-resistant packaging, (b) a capillary-containing spray head, and (c) a propellant-containing cosmetic composition containing at least one UV filter. The atomization is done using the capillary. The capillary preferably has a diameter of 0.1 to 1 mm and a length of 5 to 100 mm. The spray rate is preferably 0.01 to 5 g/s. The composition can particularly be a gel, wax, or emulsion.

Abstract: A product release system for atomizing cosmetic hair compositions is described, which has (a) pressure-resistant packaging, (b) a capillary-containing spray head, and (c) a propellant-containing cosmetic composition, which contains at least one hair-setting or hair-conditioning nonionic, anionic, amphoteric, or zwitterionic polymer. The atomization is done using the capillary. The capillary preferably has a diameter of 0.1 to 1 mm and a length of 5 to 100 mm. The spray rate is preferably 0.01 to 5 g/s. The composition can particularly be a gel, wax, or emulsion.

Abstract: The present invention refers to cooling compounds of formula I wherein R1, R2, R3, X, Y, Z, and m have the same meaning as given in the specification. The present invention refers furthermore to a process for their production and to product compositions comprising them.

Abstract: A chewable confectionery dental composition delivering to the mouth a unit dose of a plaque reducing enzyme the composition comprising an enzyme and a non-cariogenic sweetener, the enzyme being incorporated in the composition at a temperature less than about 80° C.

Abstract: A one-component prescription fluoride treatment composition having both fluoride efficacy and sensitivity relief is disclosed. The composition includes at least one metal fluoride and a nerve desensitizing agent such as potassium nitrate. The invention further includes a composition having at least one metal fluoride less than about 1.15% by weight of at least one metal fluoride; less than about 5 percent by weight of at least one alkali metal salt having desensitizing effect; at least one carrier; and at least one foaming agent that has thickening property. The composition may be formulated into a gel, a paste or any other convenient form, some of which contain abrasives.

Abstract: A dental balm composition and method prevents damage to teeth which are prone to prolonged exposure to air or other drying conditions and which are therefore susceptible to tooth decay. The dental balm composition and uses an active decay preventing agent such as fluoride ion, xylitol or glycerin dispersed in a water insoluble adhesive and protective balm base such as petrolatum along with optional thickeners, flavorants and the like. The method of damage prevention applies the balm, such as by swab or finger, to the exposed surfaces of the subject's front teeth prior to vigorous physical activity, exercise, prolonged episodes of mouth breathing, or other harsh or deleterious conditions including drying conditions during strenuous periods of exercise or tooth whitening procedures.

Abstract: Embodiments of the present invention are directed to topical oral care compositions including a free radical scavenging precursor compound.

Abstract: The invention encompasses additives for addition to a bodywash, where the additives contain one or more sunscreens, and where a bodywash which contains the additive imparts to the skin an SPF of at least about 2, in some cases at least about 5, or 10, or 15. Also described are methods of making and using the additives.

Abstract: The invention relates to complexes of certain flavonoid derivatives, of the formula (1), where R1 and R2 are selected from H and OR11, where OR11 stands, independently of one another, for OH, straight-chain or branched C1- to C20-alkoxy groups, straight-chain or branched C3- to C20-alkenyloxy groups, straight-chain or branched C1- to C20-hydroxyalkoxy groups, where the hydroxyl group(s) may be bonded to a primary or secondary carbon atom in the chain and furthermore the alkyl chain may also be interrupted by oxygen, and/or C3- to C10-cycloalkoxy groups and/or C3- to C12-cycloalkenyloxy groups, where the rings may in each case also be bridged by —(CH2)n— groups, where n=1 to 3, and/or mono- and/or oligoglycosyl radicals, with the proviso that at least one radical from R1 and R2 stands for OR11, and R3 to R10 may be identical or different and stand, independently of one another, for radicals which are substantially inert with respect to the UV properties, to compositions which comprise such complexes, to corres

Abstract: The present invention relates to polygalactomannan compositions, and more particularly guar gum compositions, which, when crosslinked with organic chelating agents, such as non-borate metal salt or chelates, to form discrete guar particles which are capable of being easily dispersed in water which permits subsequent processing of the guar, such as washing. The guar and its derivatives are desirable for use in applications such as personal care and household care products.

Abstract: The present invention relates to polygalactomannan compositions, and more particularly cationic guar gum compositions, which, when crosslinked with glyoxal, from discrete guar particles which are capable of being easily dispersed in water which permits subsequent processing of the guar, such as washing. The guar and its derivatives are desirable for use in applications such as personal care, household care products and the like.

Abstract: An anti-fungal nail lacquer composition contains a film-forming agent, a solvent, pigments and/or dyes, a glacial acetic acid of appropriate concentration dissolved in the composition. A method of utilizing the anti-fungal lacquer comprises the application of the composition to a fingernail or toenail, and allowing it to remain in contact with the nail until the solvents evaporate and the film of glacial acetic acid remains on the nail.

Abstract: Methods for providing color to animate objects, i.e., living things, as well as compositions, such as personal care compositions and agrochemical compositions, suitable for application to such animate objects. The compositions include colorants that include a radiation diffraction material comprising an ordered periodic array of particles held in a matrix, and/or a dispersion of polymer-enclosed nanoparticles.

Abstract: The cool feeling composition of the present invention obtained by combining a cool feeling substance containing at least one compound selected from 1-menthol, isopulegol, 3-(1-menthoxy)propane-1,2-diol, 2-(1-menthoxy)ethan-1-ol, 3-(1-menthoxy)propan-1-ol, 2-methyl-3-(1-menthoxy)propane-1,2-diol, N-ethyl-1-menthylcarboxamide, p-menthane-3,8-diol, 1-menthyl lactate, and 2-isopropyl-N,2,3-trimethylbutanamide with a salicylic acid ester represented by the following general formula (I), such as 2-hydroxyethyl salicylate, improves strength and persistency of cool feeling effect, particularly, those containing 1-menthol as the cool feeling substance can alleviate the irritant fragrance note resulting from 1-menthol.

Abstract: A process for manufacturing a highly water-soluble vinyl alcohol-N-vinyl amine copolymer with a degree of hydrolysis higher than 93%, including a hydrolysis reaction of a vinyl alcohol-N-vinyl formamide copolymer with an alkaline metal hydroxide in methanol wherein the process is carried out with more than 1.5 mol of the alkaline metal hydroxide per mol of N-vinyl formamide units and without addition of water. A higher water soluble vinyl alcohol-N-vinyl amine copolymer obtained by this process and the use thereof.

Abstract: The present invention relates to a composition containing a) an organo-modified silicone; b) if necessary, a C3-C22 alcohol; c) if necessary, a cationic surfactant; d) if necessary, a volatile silicone oil; e) at least 30 wt % ethanol, in relation to the total weight of the composition; as well as f) if necessary, additional additives that are different from components a to e, wherein the total quantity of components a to f is 100 wt %. The invention also relates to a process for producing a composition, the composition obtainable as a result of this process, a process to treat hair, the use of a composition to treat hair, as well as the use of a composition to produce an agent to treat hair.

Abstract: Provided are compositions comprising a low molecular weight, non-crosslinked, linear acrylic copolymer and at least one surfactant selected from the group consisting of anionic surfactants, amphoteric surfactants, and combinations of two or more thereof, and methods of using such compositions.

Abstract: Stable preparations containing omega-3 fatty acid as an effective ingredient are disclosed. Further, uses of omega-3 fatty acid in preventing or alleviating skin aging, moisturizing skin, improving skin roughness, restoring or strengthening skin barrier function, improving skin elasticity, recovering or preventing skin damage induced by UV are disclosed.

Abstract: The invention provides a delivery system for a biologically active agent comprising a gemini surfactant in admixture with the biologically active agent in a topical formulation for treatment of skin disorders or metabolic diseases. The invention also provides pharmaceutical compositions in topical formulations comprising the delivery system as set out above, in admixture with pharmaceutically acceptable carriers, diluents, excipients, or supplements suitable for application to the skin or mucosal membrane. Methods of preparation and use are also described.

Abstract: The present invention provides a unique non-viral carrier for nucleic acid delivery in vitro and in vivo, and methods of using thereof.

Abstract: The present invention concerns novel sphingolipid-polyalkylamines conjugates, a process for their preparation and pharmaceutical compositions comprising the same. In particular, the present invention concerns ceramide based polyalkylamine conjugates and its use as a capturing agent. A preferred ceramide polyalkylamine conjugate is a ceramide-spermine conjugate, more preferably, N-palmitoyl D-erythro sphingosyl-1-carbamoyl spermine.

Abstract: A method for treating gout and/or reducing serum uric acid levels in a patient is disclosed that includes administering to the patient a therapeutically effective amount of an amine polymer, for example, an aliphatic amine polymer. In one embodiment, the polymer binds to uric acid or a precursor thereof. Examples of polymers useful in an embodiment of the invention include sevelamer hydrochloride and colesevelam. The invention includes the use of amine polymers such as a cross-linked polymer characterized by a repeat unit having the formula: and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4. Also described is a use, for the manufacture of a medicament, of a polymer that binds serum uric acid in a patient.

Abstract: The present invention relates to conjugates of water-soluble polymers and o-(chloracetyl-carbamoyl) fumagillol (TNP-470) and use of those conjugates as specific intracellular carriers of the TNP-470 into tumor vessels. The present invention further relates to use of those conjugates to lower the neurotoxicity of TNP-470. Preferably, the polymer has a molecular weight in the range of 100 Da to 800 kDa. More preferably, the polymer has a molecular weight no greater than 60 kDa. Most preferably, the polymer has a molecular weight in the range of 15 kDa to 40 kDa.

Abstract: A synergistic microbicidal composition. The composition comprises a silver-containing copolymer comprising polymerized units of a monomer X and a monomer Y; wherein monomer X is an ethylenically unsaturated compound having a substituent group selected from an unsaturated or aromatic heterocyclic group having at least one hetero atom selected from N, O and S; wherein monomer Y is selected from carboxylic acids, carboxylic acid salts, carboxylic acid esters, organosulfuric acids, organosulfuric acid salts, sulfonic acids, sulfonic acid salts, phosphonic acids, phosphonic acid salts, vinyl esters, (meth)acrylamides, C8-C20 aromatic monomers containing at least one exocyclic ethylenic unsaturation and combinations thereof; and at least one organic biocide.

Abstract: A method and kits thereof for increasing the efficiency of anti-adhesive compositions by parenterally administering a composition comprising an effective amount of at least one pharmaceutically-acceptable anti-adhesive non-ionic polymer to a site of injury, controlling inflammation at the site of injury, and reducing pain.

Abstract: Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component which includes an alpha 2 adrenergic receptor agonist that is cleared from the anterior segment of an individual's eye to which the material is administered. The alpha 2 adrenergic receptor agonist may have a vitreal half-life greater than about three hours. The present materials are effective in treating an ocular condition(s) that affect the anterior segment of an eye, or the anterior and posterior segment of the eye. The materials are suitable for intravitreal or periocular administration and can provide prolonged drug delivery and therapeutic benefits to patients to which the materials have been administered. The alpha 2 adrenergic receptor agonists can be provided in liquid-containing formulations and/or bioerodible and/or non-bioerodible polymeric implants and microparticles. Methods of making and using the present materials are also described.

Abstract: Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component which includes an alpha 2 adrenergic receptor agonist that is cleared from the anterior segment of an individual's eye to which the material is administered. The alpha 2 adrenergic receptor agonist may have a vitreal half-life greater than about three hours. The present materials are effective in treating an ocular condition(s) that affect the anterior segment of an eye, or the anterior and posterior segment of the eye. The materials are suitable for intravitreal or periocular administration and can provide prolonged drug delivery and therapeutic benefits to patients to which the materials have been administered. The alpha 2 adrenergic receptor agonists can be provided in liquid-containing formulations and/or bioerodible and/or non-bioerodible polymeric implants and microparticles. Methods of making and using the present materials are also described.

Abstract: The present invention includes compositions and methods for the isolation, purification and preparation of immunogenic antigens for the production of customized cancer vaccines that include dendritic cells that are contacted with an antigen that includes heat-shocked cancer cells.

Abstract: Adjuvant compositions comprising an effective amount IL-12 and QS-21 are disclosed. Immunogenic, vaccine and pharmaceutical compositions comprising a mixture of antigen and an adjuvant composition comprising an effective amount of IL-12 and QS-21 are also disclosed. These compositions elicit functional cell-mediated and humoral immune responses against at least one antigen. Methods of using the disclosed compositions are also disclosed.

Abstract: A method is provided for introducing a GAG binding site into a protein comprising the steps: identifying a region in a protein which is not essential for structure maintenance introducing at least one basic amino acid into said site and/or deleting at least one bulky and/or acidic amino acid in said site, whereby said GAG binding site has a GAG binding affinity of Kd?10 ?M, preferably ?1 ?M, still preferred ?0.1 ?M, as well as modified GAG binding proteins.

Abstract: A method of treating a movement disorder in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of cells capable of modifying a neuronal discharge of the subject, thereby treating the movement disorder in the subject, wherein said administering is effected at a site selected from the group consisting of internal globus pallidus, subthalamic nucleus and substantia nigra pars reticulate.

Abstract: The present invention relates to a combination of compounds for introducing nucleic acids and/or protein into animal cells, tissue, organs or organisms in vitro, extracorporal, or in vivo. This combination comprises preparations suitable for administration to an animal or human for medical purposes, comprising as one component a bacterial vector genetically manipulated to contain nucleic acid sequences comprising a transgene, and a second component for the subsequent transcription, possibly translation of the transgene by controlled induction of bacterial vector as it is present within the animal or human.